Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
about
The evolving landscape of quality measurement for heart failureMineralocorticoid receptor antagonists in elderly patients with heart failure: a systematic review and meta-analysis.Managing the information boundary of an organization: key aspect of translating research into practiceTrimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone.Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study.National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010.Trends in comorbidity, disability, and polypharmacy in heart failureRetrospective review of in hospital use of mineralocorticoid receptor antagonists for high risk patients following myocardial infarctionNon-cardiac comorbidities in chronic heart failure.The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.Temporal Trends and Hospital Variation in Mineralocorticoid Receptor Antagonist Use in Veterans Discharged With Heart Failure.Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed-Methods Study.Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure.Aldosterone antagonists in heart failure.Mineralocorticoid receptor antagonists for heart failure.Implantable Cardioverter-Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review.Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study.Hypotension and Renal Dysfunction: The Ghosts of Heart Failure.LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase.
P2860
Q28680750-C9208945-DB3B-48FB-86CC-9BC22BE0381EQ34550879-5DDBBFB2-1740-4998-B8D3-8480C06BF23DQ35067769-B83CE2F2-E28F-460B-B037-3BE3D87EE8F5Q35141436-FB9A429A-E454-44D8-A0D8-F7306CB8E65BQ35208686-4D8E1B42-5555-4068-8E14-00CF7B4C9858Q35556751-77A71515-432D-4008-9FEB-717F87F98D25Q35611459-B09BF53D-3752-4C00-B167-A84403C9813EQ35659240-9B294896-2E87-4C47-9A19-0D5C70686FD2Q35954727-715E6F11-DCFD-4505-83C8-678C77208F3EQ36017400-40FE1449-9E4D-41A5-B7A1-D549CE51E4C5Q36792952-E1576277-C024-4A3D-867F-4D09619D68BCQ36836479-E2413005-E27C-4CF7-B969-AC653428E191Q37090685-5580F288-5BEF-4E13-99F9-5489969168DFQ37199205-1A9F4C7F-2548-4008-9C4A-EB661AC4A8B0Q37344514-A6C0DA93-8310-4698-ABB4-9E43D277ED95Q37585142-A8700D92-67F6-46AC-A341-5B1B76186FC6Q37821172-1B470F76-BFF9-4E2B-8880-79D68C112A70Q37955919-EBB3CB5F-63E7-422C-82E9-08E6813C762BQ39160388-B7E6C942-468A-4E93-A765-5244A316DE43Q40173081-AC5FE093-7F8A-42C9-8EFF-99E6B003CE91Q43490608-EB7EBED5-8004-4CDF-98B8-4F314E310BEAQ46789539-6ED3DE89-255D-4F7C-B145-7CD1699B99D2Q51826516-37DADFF5-F3C2-42C3-8BF6-11A548BEF9CD
P2860
Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Adoption of spironolactone the ...... the United States, 1998-2001.
@ast
Adoption of spironolactone the ...... the United States, 1998-2001.
@en
Adoption of spironolactone the ...... the United States, 1998-2001.
@nl
type
label
Adoption of spironolactone the ...... the United States, 1998-2001.
@ast
Adoption of spironolactone the ...... the United States, 1998-2001.
@en
Adoption of spironolactone the ...... the United States, 1998-2001.
@nl
prefLabel
Adoption of spironolactone the ...... the United States, 1998-2001.
@ast
Adoption of spironolactone the ...... the United States, 1998-2001.
@en
Adoption of spironolactone the ...... the United States, 1998-2001.
@nl
P2093
P921
P1433
P1476
Adoption of spironolactone the ...... the United States, 1998-2001.
@en
P2093
Cary P Gross
Edward P Havranek
Joanne Micale Foody
Saif S Rathore
Yongfei Wang
P356
10.1161/CIRCULATIONAHA.104.527549
P407
P577
2005-06-27T00:00:00Z